Stock Market Today, Feb. 18: ImmunityBio Soars After EU Approves ANKTIVA for Bladder Cancer On Feb. 18, 2026, investors weighed ImmunityBio’s EU bladder cancer win against its long slide since IPO and fresh legal scrutiny.
Why ImmunityBio Stock Is Soaring Today The biopharma outfit's flagship cancer-fighting drug continues to rack up approvals.
IBRX Gains 30% On Fresh Approval For Bladder Cancer Drug In EU: Retail, Wall Street Eyes Further Rally The European Commission granted conditional marketing authorization to ImmunityBio’s Anktiva, implying that it wants more data from the company.
IBRX Stock Jumps 6% Pre-Market On BCG Update In Saudi Arabia – Retail Says Share Price Is ‘Attractive’ The Saudi Food and Drug Authority encouraged the company to submit a regulatory filing for its recombinant Bacillus Calmette-Guérin, which the company expects to submit within weeks.
IBRX Stokes Retail Chatter — Investors See Anktiva Beat Merck’s Keytruda With Approval In EU Retail investors are now looking forward to a full approval of Anktiva in the EU for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ.
Stock Market Today, Jan. 23: ImmunityBio Falls After Gaining Over 200% in a Month Today, Jan. 23, 2026, profit taking and fresh glioblastoma survival data weighed on a soaring biotech stock.
IBRX Stock Sees Volatile Session – ImmunityBio’s Update In Phase 2 Glioblastoma Trial Sparks Buzz ImmunityBio stated that it has not yet achieved median survival in patients receiving Anktiva + CAR-NK treatment in the trial.
Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses On Jan. 21, 2026, the market weighed ImmunityBio’s skyrocketing share price, surging volume, and the company's heavily-shorted stock.
Why Is ImmunityBio Stock Back In Retail Spotlight Today? The company outlined progress across multiple cancer programs following last week's series of clinical and regulatory updates.
Stock Market Today, Jan. 16: ImmunityBio Soars After Anktiva Revenue Jumps 700 Percent Year Over Year Explosive Anktiva sales, new cancer data, and fresh approvals are rapidly redefining this immunotherapy story, today, Jan. 16, 2026.
